Marissa Collins
Biographic Data
| ID | 3582252 |
|---|---|
| NAME | Marissa Collins |
| GIVEN NAMES | Marissa |
| FAMILY NAME | Collins |
| SIGNATURE | COLLINS M |
| AFFILIATIONS | Glasgow Caledonian University |
| ORCID | 0000-0002-0896-6673 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 4 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2013 |
| LATEST PUBLICATION YEAR | 2018 |
| H-INDEX | 1 |
Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-extending, end-of-life (EoL) treatments imply that health gains from such treatments are valued more than other health gains. Despite claims that the policy is supported by societal values, evidence from preference elicitation studies is mixed and in-depth research has shown there are different societal viewpoints. Few studies elicit preferences for polic…
Resource allocation in integrated care settings: What works? Case of Health and Social Care Partnerships in Scotland
Background: The move towards integration between health and social care, as embodied in the Public Bodies (Joint Working) (Scotland) Act 2014 and similar acts in England and Wales, challenges local delivery organisations to consider the cost, quality and the value of services provided for local populations. To meet this challenge, especially when set against a background of public sector austerity, managers and staff need robust, effective framew…
OP13 An Economic Evaluation of Salt Reduction Policies to Reduce Cardiovascular Disease in England: A Policy Modelling Study
Background Dietary salt intake has been causally linked to high blood pressure and increased risk of cardiovascular events. Cardiovascular disease (CVD) causes approximately 35% of total UK deaths, at an estimated annual cost of £30 billion with £14.4 billion spent on treating CVD per year. WHO and NICE have both strongly recommended dietary salt reduction. However, to implement more effective policies in future, UK policy makers will need robust…
Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-extending, end-of-life (EoL) treatments imply that health gains from such treatments are valued more than other health gains. Despite claims that the policy is supported by societal values, evidence from preference elicitation studies is mixed and in-depth research has shown there are different societal viewpoints. Few studies elicit preferences for polic…
OP13 An Economic Evaluation of Salt Reduction Policies to Reduce Cardiovascular Disease in England: A Policy Modelling Study
Background Dietary salt intake has been causally linked to high blood pressure and increased risk of cardiovascular events. Cardiovascular disease (CVD) causes approximately 35% of total UK deaths, at an estimated annual cost of £30 billion with £14.4 billion spent on treating CVD per year. WHO and NICE have both strongly recommended dietary salt reduction. However, to implement more effective policies in future, UK policy makers will need robust…
Resource allocation in integrated care settings: What works? Case of Health and Social Care Partnerships in Scotland
Background: The move towards integration between health and social care, as embodied in the Public Bodies (Joint Working) (Scotland) Act 2014 and similar acts in England and Wales, challenges local delivery organisations to consider the cost, quality and the value of services provided for local populations. To meet this challenge, especially when set against a background of public sector austerity, managers and staff need robust, effective framew…
Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-extending, end-of-life (EoL) treatments imply that health gains from such treatments are valued more than other health gains. Despite claims that the policy is supported by societal values, evidence from preference elicitation studies is mixed and in-depth research has shown there are different societal viewpoints. Few studies elicit preferences for polic…
Economics (2 works) · Legislation (2 works) · Medicine (2 works) · Political science (2 works) · Austerity (1 works) · Baseline (sea) (1 works) · Blood pressure (1 works) · Business (1 works) · Computer Science (1 works) · Dietary salt (1 works)